Free Newsletter
Drug used to treat COPD increases mortality
The drug ipratropium bromide (Atrovent, Combivent) significantly raised the risk of mortality by cardiovascular death in patients undergoing COPD treatment, according to researchers. In addition, exposure to the medication theophylline was associated with an increased risk of respiratory death, but not cardiovascular death.
The Annals of Internal Medicine published the study findings in the September 16, 2008 issue. The findings are the result of a large-scale study of U.S. Veterans Health Administration health care system patient data.
Researchers followed a cohort of patients enrolled in the U.S. Veterans Health Administration health care system to assess mortality rates at one year.
It remains unclear if the elevated risk applies to women or patients with longstanding or severe COPD. The researchers found a 34 percent increased risk of cardiovascular death and all-cause mortality in patients using the medication to relieve the symptoms of COPD.
On the other hand, inhaled corticosteroids, the researchers found, were associated with a 20 percent decrease in cardiovascular and all cause mortality.
- see the Annals of Internal Medicine release
- read the Medpage Today article
- find the study abstract at PubMed
Related Articles:
Sepracor inks $47M IP licensing deal with Arrow
Theravance wins $10M milestone on Phase II data
FDA rejects GSK's Advair for COPD (Aug 2007)
Advair fails to hit goal in COPD trial (Mar 2007)
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: